Wyniki wyszukiwania

1

Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affetcs growth of B16-F10 tumors

100%

Mitrus I., Sochanik A., Cichon T., Szala S.

Acta Biochimica Polonica

|

2009

|

tom 56

|

nr 1

161-165

The study aimed to check the effectiveness of anticancer therapy combining a vascular-disruptive drug (combretastatin phosphate, CA4P) and a liposomal formulation of a chemotherapeutic (doxorubicin). CA4P was synthesized in our laboratory according to a previously described procedure. The antivascular drug and long-circulating doxorubicin-loaded liposomes were used to treat B16-F10 murine melanoma experimental tumors. Seventy-four hours after drug administration, a decrease in the number of tumor blood vessels was apparent and necrotic areas within tumors were visible. Combination therapy consisting of alternate administrations of CA4P and liposomal doxorubicin yielded greater inhibition of tumor growth than monotherapies alone. The best therapeutic results were obtained with the antivascular drug administered intratumorally every second day at 50 mg/kg body mass. In the case of combined therapy, the best results were obtained when the vascular-disruptive agent (CA4P) and the antineoplastic agent (liposomal doxorubicin) were administered in alternation.

2

Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16[F10] melanoma tumors in mice

84%

Mitrus I., Delic K., Wrobel N., Missol-Kolka E., Szala S.

Acta Biochimica Polonica

|

2006

|

tom 53

|

nr 2

We investigated suppression of murine B16(F10) melanoma tumor growth following a therapy which involved concomitant administration of cyclophosphamide and plasmid DNA bearing interleukin-12 gene. Since both therapeutic factors display antiangiogenic capabilities, we assumed that their use in blocking the formation of new blood vessels would result in augmented inhibition of tumor growth. This combined therapy regimen indeed resulted in a considerable suppression of tumor growth. We observed a statistically significant extension of treated animals' lifespan. Interestingly, the therapeutic effect was also obtained using a plasmid without an interleukin gene insert. This observation suggests that plasmid DNA, which has been widely applied for treating neoplastic tumors, contains element(s) that elicit immune response in mice.

3

Combined methotrexate and coenzyme Q10 therapy in adjuvant-induced arthritis evaluated using parameters of inflammation and oxidative stress

67%

Bauerova K., Paulovicova E., Mihalova D., Drafi F., Strosova M., Mascia C., Biasi F., Rovensky J., Kucharska J., Gvozdjakova A., Ponist S.

Acta Biochimica Polonica

|

2010

|

tom 57

|

nr 3

Rheumatoid arthritis is a common severe joint disease that affects all age groups, it is thus of great importance to develop new strategies for its treatment. The aim of the present study was to examine the combined effect of coenzyme Q10 (CoQ10) and methotrexate (MTX) on the progression of adjuvant-induced arthritis in rats. Adjuvant arthritis (AA) was induced by a single intradermal injection of heat-inactivated Mycobacterium butyricum in incomplete Freund's adjuvant. The experiments included healthy animals, arthritic animals not treated, arthritic animals treated with CoQ10, with methotrexate, and with a combination of CoQ10 and methotrexate. The two latter groups received a daily oral dose of 20 mg/kg b.w. of CoQ10, either alone or with methotrexate in an oral dose of 0.3 mg/kg b.w. twice a week. We found that CoQ10 potentiated both the antiarthritic (decrease of hind paw volume) and the antioxidant effect of methotrexate on the level of oxidation of proteins (suppression of protein carbonyl level in plasma) as well as lipoperoxidation (suppression of levels of HNE-adducts and MDA-adducts to plasma proteins). The same effect was observed for plasmatic levels of CoQ9 and IL-1α, and partially also for γ-glutamyltransferase activity assessed in joints and spleen. Moreover, the combination therapy improved the functionality of peripheral blood neutrophils in AA, with a balancing effect on the immunosuppression caused by MTX monotherapy. In summary, combined administration of CoQ10 and methotrexate suppressed arthritic progression in rats more effectively than did MTX alone. This finding may help improve treatment of rheumatoid arthritis.

4

Postepy w skojarzonym leczeniu nowotworow

67%

Jassem J.

Acta Biologica et Medica

|

1992

|

tom 18

69-78

5

Combined therapy with disintegrin and melphalan as a new strategy in inhibition of endometrial cancer cell line (Ishikawa) growth

67%

Miltyk W., Surazynski A., Wolczynski S., Palka J. A.

Folia Histochemica et Cytobiologica

|

2009

|

tom 47

|

nr 5

6

Napad drgawkowy: czemu i jak należy leczyć, czyli przegląd aktualnych wytycznych

51%

Pawelec H., Pomianowski A.

Weterynaria w Praktyce

|

2020

|

tom 17

|

nr 06

Ograniczanie wyników

Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affetcs growth of B16-F10 tumors

Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16[F10] melanoma tumors in mice

Combined methotrexate and coenzyme Q10 therapy in adjuvant-induced arthritis evaluated using parameters of inflammation and oxidative stress

Postepy w skojarzonym leczeniu nowotworow

Combined therapy with disintegrin and melphalan as a new strategy in inhibition of endometrial cancer cell line (Ishikawa) growth

Napad drgawkowy: czemu i jak należy leczyć, czyli przegląd aktualnych wytycznych